High-dose cholinergic therapy with rivastigmine patch does not prolong QTc time in patients with Alzheimer's disease.
Division of Mental Health & Old Age Psychiatry, Psychiatry II, Ulm University, Günzburg, Germany matthias.riepe@uni-ulm.de.
Matthias W
MW
Riepe
D000544:Alzheimer Disease / Q000188:drug therapy*; D002800:Cholinesterase Inhibitors / Q000008:administration & dosage / Q000009:adverse effects*; D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D055724:Electrophysiological Phenomena / Q000187:drug effects*; D006321:Heart / Q000187:drug effects* / Q000503:physiopathology; D006801:Humans; D008133:Long QT Syndrome / Q000139:chemically induced; D048448:Phenylcarbamates / Q000008:administration & dosage / Q000009:adverse effects*; D000068836:Rivastigmine; D057968:Transdermal Patch
D002800:Cholinesterase Inhibitors; D048448:Phenylcarbamates; D000068836:Rivastigmine